Back to top
more

Infinity Pharmaceuticals, Inc. (INFI)

(Delayed Data from NSDQ)

$1.71 USD

1.71
99,328

+0.06 (3.64%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.72 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Why Is Infinity Pharmaceuticals (INFI) Down 18.3% Since its Last Earnings Report?

Infinity Pharmaceuticals (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Why Infinity Pharmaceuticals (INFI) Could Shock the Market Soon

    Infinity Pharmaceuticals (INFI) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

      Karyopharm's Myeloma Candidate Gets Fast Track Designation

      The FDA grants a fast track status to Karyopharm's (KPTI) selinexor for treatment of multiple myeloma. Selinexor is also evaluated in several mid- and later-phase studies on multiple cancer indications.

        FDA Prolongs Review Date for AbbVie Endometriosis Candidate

        The FDA extends the review period of NDA for AbbVie (ABBV) and partner Neurocrine Biosciences' endometriosis candidate, elagolix, by three months to third-quarter 2018.

          Are Options Traders Betting on a Big Move in Infinity Pharmaceuticals (INFI) Stock?

          Investors in Infinity Pharmaceuticals (INFI) need to pay close attention to the stock based on moves in the options market lately.

            Can The Uptrend Continue for Infinity Pharmaceuticals (INFI)?

            Investors certainly have to be happy with Infinity Pharmaceuticals, Inc. (INFI) and its short term performance

              Infinity (INFI) Reports Narrower-than-Expected Loss in Q4

              Infinity (INFI) incurs narrower-than-expected Loss in Q4 and expects to report data from the monotherapy expansion and combination dose escalation components of its pipeline candidate IPI-549.

                Infinity Provides Update on Lead Candidate, Issues 2018 View

                Infinity (INFI) announces the achievement of some development milestones for its lead pipeline candidate- IPI-549 and issued financial guidance for 2018.

                  Options Traders Expect Huge Moves in Infinity Pharmaceuticals (INFI) Stock

                  Surging implied volatility makes Infinity Pharmaceuticals (INFI) stock lucrative to the option traders.

                    Infinity (INFI) Q3 Loss Narrower than Expected, View Intact

                    Infinity Pharmaceuticals (INFI) Q3 loss was narrower than estimates and the year-ago quarter loss.

                      Seattle Genetics Inks Clinical Collaborations for Cancer Drug

                      Seattle Genetics (SGEN) announced two clinical collaborations to evaluate SGN-LIV1A in triple negative breast cancer.

                        Infinity Pharmaceuticals, Inc. (INFI) in Focus: Stock Moves 12% Higher

                        Infinity Pharmaceuticals, Inc. (INFI) saw its shares rise nearly 12% on the day.

                          Infinity/ Bristol-Myers Adds TNBC Patients to Clinical Deal

                          Infinity (INFI) expanded its existing clinical collaboration with Bristol-Myers Squibb for evaluating IPI-549 in combination with Opdivo to include patients with triple negative breast cancer.

                            Infinity (INFI) Q2 Loss Wider than Expected, View Intact

                            Infinity Pharmaceuticals, Inc. (INFI) reported a wider-than-expected loss in second-quarter 2017 due to the termination of an agreement with AbbVie.

                              Infinity Pharmaceuticals (INFI) Down 5.3% Since Earnings Report: Can It Rebound?

                              Infinity Pharmaceuticals (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                Catalyst Pharmaceuticals (CPRX) Posts Loss as Expected in Q1

                                Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 6 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate but narrower than the loss of 7 cents in the year-ago quarter.

                                  Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1

                                  Endocyte, Inc. (ECYT) reported a narrower-than-expected loss in the first quarter of 2017.

                                    Valeant (VRX) Q1 Earnings & Revenues Miss, View Raised

                                    Shares of Valeant Pharmaceuticals Inc. (VRX) surged significantly after the company raised the annual guidance for 2017 concurrent with the first-quarter 2017 earnings.

                                      Infinity (INFI) Reports Narrower-than-Expected Loss in Q1

                                      Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 21 cents per share in first-quarter 2017, narrower than the Zacks Consensus Estimate loss of 22 cents. Also, the company had reported loss of 82 cents in the year-ago quarter.

                                        Endo (ENDP) Beats on Q1 Earnings, Reaffirms '17 Guidance

                                        Endo International plc's (ENDP) first-quarter 2017 earnings from continuing operations was $1.23 per share which topped the Zacks Consensus Estimate of $1.12. Earnings were also above the year-ago figure of $1.08.

                                          Horizon (HZNP) Falls on Q1 Earnings Miss, Guidance Trimmed

                                          Horizon Pharma plc (HZNP) reported first-quarter 2017 earnings of 21 cents per share, down from 25 cents in the year-ago quarter. Reported earnings also missed the Zacks Consensus Estimate of 25 cents.

                                            Catalent (CTLT) Shows Strength: Stock Adds 9.8% in Session

                                            Catalent, Inc. (CTLT) shares rose almost 10% in the last trading session.

                                              Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Beat

                                              Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.61 per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of $4.27.

                                                Agenus (AGEN) Reports Narrower-than-Expected Loss in Q1

                                                Agenus Inc. (AGEN) reported first-quarter 2017 loss of 18 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 32 cents and the year-ago loss of 37 cents.

                                                  Regeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates

                                                  Regeneron Pharmaceuticals, Inc. (REGN) reported first-quarter 2017 results wherein earnings missed estimates while revenues beat expectations.